Your browser is no longer supported. Please, upgrade your browser.
Settings
SNDX [NASD]
Syndax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own0.40% Shs Outstand51.50M Perf Week-6.61%
Market Cap866.61M Forward P/E- EPS next Y-2.19 Insider Trans-18.95% Shs Float45.41M Perf Month-1.07%
Income-85.60M PEG- EPS next Q-0.71 Inst Own- Short Float16.58% Perf Quarter-27.34%
Sales1.50M P/S577.74 EPS this Y-1.50% Inst Trans4.29% Short Ratio9.01 Perf Half Y-30.73%
Book/sh4.43 P/B3.98 EPS next Y6.00% ROA-36.00% Target Price28.00 Perf Year16.58%
Cash/sh5.63 P/C3.14 EPS next 5Y- ROE-45.10% 52W Range13.02 - 27.85 Perf YTD-20.64%
Dividend- P/FCF- EPS past 5Y20.80% ROI-26.20% 52W High-36.62% Beta1.60
Dividend %- Quick Ratio11.40 Sales past 5Y19.30% Gross Margin- 52W Low35.56% ATR0.97
Employees43 Current Ratio11.40 Sales Q/Q0.00% Oper. Margin- RSI (14)42.80 Volatility5.77% 4.71%
OptionableYes Debt/Eq0.09 EPS Q/Q3.50% Profit Margin- Rel Volume0.42 Prev Close19.23
ShortableYes LT Debt/Eq0.07 EarningsMay 11 AMC Payout- Avg Volume835.57K Price17.65
Recom1.70 SMA20-5.05% SMA50-1.19% SMA200-12.32% Volume368,659 Change-8.22%
Jun-04-21Resumed Robert W. Baird Outperform $30 → $31
May-25-21Initiated Citigroup Buy $24
Feb-18-21Initiated B. Riley Securities Buy $30
Dec-03-20Initiated Stifel Buy $32
May-22-20Upgrade Citigroup Neutral → Buy $26 → $23
May-22-20Downgrade H.C. Wainwright Buy → Neutral $25 → $15
May-18-20Downgrade Citigroup Buy → Neutral
May-11-20Reiterated H.C. Wainwright Buy $19 → $25
Mar-04-20Initiated Barclays Overweight $15
Jan-13-20Reiterated H.C. Wainwright Buy $15 → $17
Mar-08-19Reiterated H.C. Wainwright Buy $22 → $16
Jan-04-19Initiated Robert W. Baird Outperform
Jan-05-18Initiated B. Riley FBR, Inc. Buy $40
Mar-16-17Initiated FBR & Co. Outperform $27
Mar-02-17Initiated Instinet Buy $27
Oct-07-16Initiated Guggenheim Buy
Mar-28-16Initiated Morgan Stanley Overweight $22
Mar-28-16Initiated JMP Securities Mkt Outperform $28
Mar-28-16Initiated Citigroup Buy $24
Jun-07-21 08:38PM  
Jun-03-21 07:00AM  
May-13-21 07:00AM  
May-12-21 07:51AM  
May-11-21 04:01PM  
02:30PM  
May-04-21 07:00AM  
Apr-25-21 03:42AM  
Apr-22-21 08:48AM  
Apr-20-21 04:18PM  
09:40AM  
07:00AM  
Apr-15-21 07:00AM  
Apr-09-21 09:40AM  
08:12AM  
Apr-08-21 04:30PM  
01:38PM  
Apr-01-21 08:17AM  
Mar-31-21 07:00AM  
Mar-15-21 08:51AM  
Mar-09-21 03:38AM  
Mar-08-21 04:37PM  
04:05PM  
01:30PM  
Mar-06-21 10:57AM  
Mar-01-21 07:00AM  
Feb-24-21 07:00AM  
Dec-18-20 07:00AM  
Dec-11-20 04:30PM  
Dec-09-20 06:30AM  
Dec-08-20 08:03AM  
Dec-07-20 04:31PM  
08:54AM  
Dec-06-20 12:30PM  
Dec-03-20 09:56AM  
Nov-30-20 07:00AM  
Nov-11-20 07:00AM  
Nov-04-20 04:05PM  
Nov-02-20 04:05PM  
02:30PM  
Oct-26-20 07:00AM  
Oct-21-20 11:26AM  
Sep-29-20 11:20AM  
Sep-03-20 02:51PM  
Sep-02-20 07:00AM  
Aug-06-20 04:05PM  
Aug-04-20 11:13AM  
Aug-03-20 07:00AM  
Jul-30-20 07:00AM  
Jul-07-20 07:00AM  
Jun-23-20 07:27PM  
Jun-10-20 12:14AM  
May-25-20 03:17PM  
May-22-20 04:17PM  
May-21-20 04:35PM  
May-12-20 04:05PM  
May-09-20 10:31PM  
May-07-20 08:10PM  
04:05PM  
Apr-30-20 07:51AM  
07:00AM  
Apr-29-20 04:35PM  
08:40AM  
Apr-28-20 04:09PM  
03:09PM  
12:52PM  
07:36AM  
Apr-27-20 04:05PM  
12:31PM  
Apr-14-20 07:00AM  
Apr-03-20 06:04PM  
Mar-05-20 06:54AM  
Mar-03-20 05:55PM  
04:05PM  
Feb-18-20 07:00AM  
Feb-07-20 11:05AM  
Feb-04-20 07:01AM  
Jan-31-20 07:00AM  
Jan-30-20 02:11PM  
Jan-24-20 10:20AM  
Jan-10-20 04:05PM  
Dec-17-19 04:39PM  
Dec-10-19 08:08AM  
07:00AM  
Dec-09-19 04:05PM  
Nov-17-19 07:14AM  
Nov-11-19 09:30AM  
Nov-07-19 05:55PM  
04:05PM  
Nov-06-19 07:00AM  
Oct-31-19 07:00AM  
Oct-28-19 10:32AM  
Oct-23-19 12:44PM  
Sep-17-19 11:42AM  
Sep-11-19 10:04AM  
Aug-29-19 11:41AM  
Aug-28-19 07:00AM  
Aug-12-19 08:46AM  
Aug-09-19 09:37AM  
Aug-07-19 06:25PM  
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyers Michael L.SVP, Chief Medical OfficerApr 26Buy15.465007,73015,666Apr 28 04:15 PM
Podlesak DennisDirectorApr 22Buy14.1113,967197,07743,300Apr 22 05:06 PM
Egros FabriceDirectorMar 01Option Exercise6.3610,24165,09326,241Mar 03 04:16 PM
Egros FabriceDirectorMar 01Sale24.3110,241248,98116,000Mar 03 04:16 PM
Morrison BriggsChief Executive OfficerFeb 08Option Exercise7.2035,156253,12383,492Feb 10 04:23 PM
Morrison BriggsChief Executive OfficerFeb 08Sale20.5535,156722,40348,336Feb 10 04:23 PM
Metzger Michael APresident and COOFeb 01Option Exercise7.2015,000108,00032,659Feb 03 05:53 PM
Metzger Michael APresident and COOFeb 01Sale20.1915,000302,79917,659Feb 03 05:53 PM
Metzger Michael APresident and COODec 01Option Exercise7.2015,000108,00032,659Dec 03 06:05 PM
Metzger Michael APresident and COODec 01Sale22.9715,000344,51217,659Dec 03 06:05 PM
Ordentlich PeterChief Scientific OfficerNov 23Option Exercise3.0829,97292,31429,972Nov 25 04:38 PM
Ordentlich PeterChief Scientific OfficerNov 23Sale23.1629,972694,1210Nov 25 04:38 PM
Morrison BriggsChief Executive OfficerNov 10Option Exercise7.2017,466125,75564,031Nov 12 05:55 PM
Morrison BriggsChief Executive OfficerNov 10Sale20.0617,466350,31246,565Nov 12 05:55 PM
Morrison BriggsChief Executive OfficerNov 09Option Exercise7.2062,938453,154109,503Nov 12 05:55 PM
Morrison BriggsChief Executive OfficerNov 09Sale20.0462,9381,261,26546,565Nov 12 05:55 PM
Metzger Michael APresident and COONov 04Option Exercise7.20100,000720,000117,659Nov 06 05:55 PM
Metzger Michael APresident and COONov 04Sale20.31100,0002,031,41017,659Nov 06 05:55 PM